Bio News
China’s Henlius Biotech has signed a co-development agreement for T-cell engager (TCE) antibodies with U.S.-based Amberstone Biosciences.
Using its proprietary T-Mate platform, Amberstone Biosciences will develop preclinical TCEs against up to two targets selected by Henlius Biotech.
Amberstone Biosciences will receive up to $440 million, including an upfront payment and development, regulatory and sales milestone payments.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
